EUVIMEDEUVIMED entdecken
Vergleichsstudie

Preemptive Versus Empirical Antifungal Therapy for High‐Risk, Febrile, Neutropenic Solid Tumor Patients in an LMIC Setting

Omnia Al-Qadi iD, Lobna Shalaby, Mervat El Anany, Iman Zaky, Maggie Naguib, Amr Kashef iD, Omneya Hassanain, Manal Zamzam, Leslie Lehmann, Alaa El Haddad

Pediatric Blood & Cancer · 2026

DOI: 10.1002/1545-5017.70095 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Pediatric Blood & Cancer, 2026. Verfasst von Omnia Al-Qadi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Oncology Department and Pediatric Stem Cell Transplantation Unit, Children's Cancer Hospital Egypt (CCHE 57357), Cairo, Egypt. Hauptthemen laut MEDLINE: Antifungal Agents, Neoplasms, Invasive Fungal Infections, Neutropenia. Die Arbeit nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Preemptive antifungal therapy in neutropenic fever offers a rational alternative to the empiric strategy, potentially reducing drug toxicity, resistance, and treatment‐related costs. However, its implementation in the Middle East and North Africa (MENA) region remains insufficiently addressed.

Methods

We prospectively observed episodes of neutropenia in pediatric patients with solid tumors and prolonged neutropenia. This non‐inferiority cohort study evaluated two primary endpoints: the cumulative incidence of invasive fungal infection (IFI), IFI‐attributable mortality. Outcomes from the prospective cohort managed with a preemptive strategy were compared with retrospective data from a historical cohort treated with the previously used empiric approach.

Results

A total of 422 preemptive episodes were prospectively recorded, and data from 338 historical empiric episodes were retrospectively reviewed. The incidence of IFI was comparable between the two groups (4.5% in the preemptive group vs. 5.6% in the empiric group; p = 0.5). However, antifungal use was significantly lower in the preemptive group (5.0% vs. 58.0%; p < 0.001). Overall survival was higher in the preemptive group (98.9% vs. 94.6%). No IFI‐attributable mortality was recorded in either group.

Interpretation

The combined EIA/HRCT‐based preemptive strategy is feasible and associated with reduced antifungal use without compromising patient outcomes in pediatric patients with solid tumors and prolonged neutropenia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsNeoplasmsInvasive Fungal InfectionsNeutropeniaFeverHumansMaleFemaleChildChild, PreschoolAdolescentProspective StudiesRetrospective StudiesInfantSurvival RateFollow-Up StudiesPrognosisMiddle EastIncidence

Stichwörter der Autor:innen

EIA/HRCT‐based preemptive strategyLMICMENAinvasive fungal infectionneutropenic feverpediatric oncologypreemptive antifungal therapy

Substanzen

Antifungal Agents

Autor:innen und Institutionen

  • Pediatric Oncology Department and Pediatric Stem Cell Transplantation Unit, Children's Cancer Hospital Egypt (CCHE 57357), Cairo, Egypt.
  • Pediatric Oncology Department and Hematopoietic Stem Cell Transplantation, National Cancer Institute (NCI), Cairo University, Cairo, Egypt.
  • Microbiology Department, Children's Cancer Hospital Egypt (CCHE 57357), Cairo, Egypt.
  • Radiology Department, Children's Cancer Hospital Egypt (CCHE 57357), Cairo, Egypt.
  • Pediatrics Department, Faculty of Medicine, Cairo University Children's Hospital, Cairo, Egypt.
  • Pediatric Pulmonology Department, Children's Cancer Hospital Egypt (CCHE 57357), Cairo, Egypt.

ORCID-Profile: Omnia Al-Qadi, Amr Kashef

Zitieren

APA

Al-Qadi, O., Shalaby, L., Anany, M. E., Zaky, I., Naguib, M., Kashef, A., Hassanain, O., Zamzam, M., Lehmann, L., & Haddad, A. E. (2026). Preemptive Versus Empirical Antifungal Therapy for High‐Risk, Febrile, Neutropenic Solid Tumor Patients in an LMIC Setting. Pediatric Blood & Cancer. https://doi.org/10.1002/1545-5017.70095

Vancouver

Al-Qadi O, Shalaby L, Anany ME, Zaky I, Naguib M, Kashef A, et al. Preemptive Versus Empirical Antifungal Therapy for High‐Risk, Febrile, Neutropenic Solid Tumor Patients in an LMIC Setting. Pediatric Blood & Cancer. 2026. doi:10.1002/1545-5017.70095

BibTeX
@article{AlQadi2026,
  author = {Al-Qadi, Omnia and Shalaby, Lobna and Anany, Mervat El and Zaky, Iman and Naguib, Maggie and Kashef, Amr and Hassanain, Omneya and Zamzam, Manal and Lehmann, Leslie and Haddad, Alaa El},
  title = {Preemptive Versus Empirical Antifungal Therapy for High‐Risk, Febrile, Neutropenic Solid Tumor Patients in an LMIC Setting},
  journal = {Pediatric Blood & Cancer},
  year = {2026},
  doi = {10.1002/1545-5017.70095}
}
Kostenlos starten →